A Phase 3 interventional study of CTx-1301-Dexmethylphenidate 12.5 mg (titration only) and CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) in ADHD, Attention Deficit Hyperactivity Disorder and ADHD - Combined Type, sponsored by Cingulate Therapeutics. Completed at 24 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Cingulate Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 283rd largest by enrollment of the 706 interventional ones that give a count, is one of 30 that started in 2023, is one of 121 in phase 3, and was the 654th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–17
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–13
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Alkermes, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
807 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 108 · Phase 3 135 · Phase 4 148
First in 1985; this study’s year is marked. 30 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 70 across the 706 interventional studies, 115 across the 98 observational. Of the 644 that completed or were terminated, 302 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
262 of 807 have an industry lead sponsor. The 10 most frequent:
Cingulate Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Cingulate Therapeutics has 4 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
34 of the studies in Attention Deficit Disorder with Hyperactivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04946253University of PittsburghSKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care | 2026-11 |
| NCT05683756University of PittsburghOptimizing Attention and Sleep Intervention Study | 2026-12 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
Add all 34 to your calendar (.ics) → With an account.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (d-MPH). The study will be comprised of a screening period, a double-blind randomized phase, and a safety follow-up visit.
A Phase 3, double-blind, randomized, placebo-controlled, multi-center, fixed-dose, parallel group efficacy and safety study in pediatrics (6-17) with ADHD diagnosis confirmed by an ADHD-RS-5 score of at least 28 and CGI-S score of at least 4 (moderately ill) at screening. The study will be comprised of a screening period, a double-blind randomized phase, and a safety follow-up visit.
The Study will be comprised of 3 periods:
Subjects will participate in the study as outpatients for up to approximately 10 weeks (including screening); a 30-day screening period, a 5-week double-blind randomized period, and a 1-week follow-up safety visit.
Completion of the primary study is defined as LSLV at Visit 9.
Subjects will be randomized at baseline to CTx-1301 or placebo (CTx-1301 18.75 mg, CTx-1301 25 mg, CTx-1301 37.5 mg, or placebo). Starting dose for subjects randomized to active treatment is 12.5 mg. These subjects will then be titrated up to their assigned fixed dose (18.75, 25, or 37.5 mg) for the last two weeks of the study period. Subjects randomized to placebo will receive placebo treatment for the full 5 weeks of the study.
Sparse PK sampling will be conducted after a single dose and at steady state from the patient population with special attention given to the time the sample is obtained post-dose. These analyses will inform strategies that manage dosing and detail administration for a given subpopulation, planned subsequent studies, and support labeling.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who are randomized to active drug (18.75 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to their assigned dose of 18.75 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
Drug: CTx-1301-Dexmethylphenidate 12.5 mg (titration only) · Drug: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)
Subjects who are randomized to active drug (25 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to their assigned dose of 25 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
Drug: CTx-1301-Dexmethylphenidate 12.5 mg (titration only) · Drug: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) · Drug: CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
Subjects who are randomized to active drug (37.5 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to 25 mg; at week 3 they will be increased to their assigned dose of 37.5 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
Drug: CTx-1301-Dexmethylphenidate 12.5 mg (titration only) · Drug: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) · Drug: CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) · Drug: CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)
Subjects randomized to placebo will be on placebo for the full 5 weeks of the study.
Drug: Placebo
Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
Also known as: d-MPH
Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
Also known as: d-MPH
Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg
Also known as: d-MPH
Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg
Also known as: d-MPH
Subjects will be randomized at Visit 2 to Placebo
The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5) Scores to ADHD-RS-5 at Visit 8.
The Attention Deficit Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5) overall scores range from 0-54; an improvement from Baseline is defined as a decrease in the overall score.
Time frame: Baseline (Day 0) to Week 5 (Visit 8)
The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.
The Clinical Global Impression - Severity (CGI-S) is a single score ranging from 1-7; an improvement from Baseline is defined as a decrease in the score.
Time frame: Baseline (Day 0) to Week 5 (Visit 8)
Safety - Number of Subjects With Clinically Significant Changes in Vital Signs That Resulted in an Adverse Event.
Vital signs will be evaluated in each in-office visit; clinically significant changes will be recorded as an adverse event.
Time frame: Baseline to Visit 8 (5 weeks)
Safety - Number of Subjects With Clinically Significant Changes in Blood Labs That Resulted in an Adverse Event.
Safety labs will be taken at Screening to determine eligibility for entry into the study; safety labs are assessed again at Visit 8 and any clinically significant change from Screening labs will be recorded as an adverse event.
Time frame: Screening to Visit 8 (approximately 5-9 weeks, depending on screening window)
Safety - Number of Subjects With Clinically Significant Changes in Physical Exam Findings That Resulted in an Adverse Event.
Physical exams will be conducted at Screening, Baseline, and Visit 8. Changes noted as clinically significant from Baseline to Visit 8 will be recorded as an adverse event.
Time frame: Baseline to Visit 8 (5 weeks)
Safety - Number of Subjects With Clinically Significant Changes in Height and Weight BMI That Resulted in an Adverse Event.
Height and Weight (BMI) will be evaluated at all in-office visits. Any clinically significant change in BMI from Baseline to Visit 8 will be recorded as an AE.
Time frame: Baseline to Visit 8 (5 weeks)
Safety - Number of Subjects With Clinically Significant Changes in C-SSRS Findings That Resulted in an Adverse Event.
C-SSRS will be conducted at all in-office visits. Any clinically significant change from Baseline (at any visit) will be reported as an AE.
Time frame: Baseline to Visit 8 (5 weeks)
Safety - Number of Subjects With Clinically Significant Changes in ECG Findings That Resulted in an Adverse Event.
ECGs will be taken at Screening to determine eligibility for entry into the study; ECGs are assessed again at Visit 8 and any clinically significant change from Screening ECG will be recorded as an adverse event.
Time frame: Screening to Visit 8 (approximately 5-9 weeks, depending on screening window)
Safety - Incidence of TEAEs
Treatment Emergent Adverse Events will be evaluated at each visit.
Time frame: Screening to Visit 9 (approximately 6-10 weeks, depending on screening window)
Although approximately 385 subjects were expected to enroll in the study, the study was completed with 103 subjects enrolled after an agreement was reached with FDA on the requirements necessary for filing an NDA for CTx-1301. Subjects were recruited at 24 sites from August 1, 2023 to December 13, 2023.
| Milestone | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Started | 26 | 26 | 25 | 26 |
| Completed | 21 | 24 | 21 | 22 |
| Not completed | 5 | 2 | 4 | 4 |
The Attention Deficit Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5) overall scores range from 0-54; an improvement from Baseline is defined as a decrease in the overall score.
| score on a scale | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5) Scores to ADHD-RS-5 at Visit 8. | -18.0 ± 12.24 | -17.8 ± 12.78 | -22.0 ± 15.07 | -8.1 ± 13.88 |
The Clinical Global Impression - Severity (CGI-S) is a single score ranging from 1-7; an improvement from Baseline is defined as a decrease in the score.
| score on a scale | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8. | -1.5 ± 1.33 | -1.5 ± 1.22 | -2.2 ± 1.57 | -0.8 ± 1.34 |
Vital signs will be evaluated in each in-office visit; clinically significant changes will be recorded as an adverse event.
| Participants | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Safety - Number of Subjects With Clinically Significant Changes in Vital Signs That Resulted in an Adverse Event. | 2 | 2 | 3 | 1 |
Safety labs will be taken at Screening to determine eligibility for entry into the study; safety labs are assessed again at Visit 8 and any clinically significant change from Screening labs will be recorded as an adverse event.
| Participants | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Safety - Number of Subjects With Clinically Significant Changes in Blood Labs That Resulted in an Adverse Event. | 0 | 0 | 1 | 1 |
Physical exams will be conducted at Screening, Baseline, and Visit 8. Changes noted as clinically significant from Baseline to Visit 8 will be recorded as an adverse event.
| Participants | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Safety - Number of Subjects With Clinically Significant Changes in Physical Exam Findings That Resulted in an Adverse Event. | 11 | 14 | 17 | 8 |
Height and Weight (BMI) will be evaluated at all in-office visits. Any clinically significant change in BMI from Baseline to Visit 8 will be recorded as an AE.
| Participants | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Safety - Number of Subjects With Clinically Significant Changes in Height and Weight BMI That Resulted in an Adverse Event. | 0 | 0 | 2 | 0 |
C-SSRS will be conducted at all in-office visits. Any clinically significant change from Baseline (at any visit) will be reported as an AE.
| Participants | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Safety - Number of Subjects With Clinically Significant Changes in C-SSRS Findings That Resulted in an Adverse Event. | 0 | 0 | 1 | 0 |
ECGs will be taken at Screening to determine eligibility for entry into the study; ECGs are assessed again at Visit 8 and any clinically significant change from Screening ECG will be recorded as an adverse event.
| Participants | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Safety - Number of Subjects With Clinically Significant Changes in ECG Findings That Resulted in an Adverse Event. | 1 | 2 | 1 | 1 |
Treatment Emergent Adverse Events will be evaluated at each visit.
| Participants | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Safety - Incidence of TEAEs | 13 | 9 | 17 | 10 |
Collected over Day -30 to Day 42. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 0/26 (0%) | 0/26 (0%) | 13/26 (50%) |
| 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 0/26 (0%) | 0/26 (0%) | 9/26 (34.6%) |
| 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | 0/25 (0%) | 0/25 (0%) | 17/25 (68%) |
| Placebo | 0/26 (0%) | 0/26 (0%) | 10/26 (38.5%) |
| Event | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 3/26 | 5/26 | 7/25 | 0/26 |
| Abdominal pain upperGastrointestinal disorders | 1/26 | 1/26 | 4/25 | 2/26 |
| HeadacheNervous system disorders | 3/26 | 0/26 | 1/25 | 3/26 |
| Blood pressure increasedInvestigations | 1/26 | 0/26 | 2/25 | 1/26 |
| Weight decreasedInvestigations | 0/26 | 0/26 | 2/25 | 0/26 |
| NasopharyngitisInfections and infestations | 0/26 | 0/26 | 1/25 | 2/26 |
| AnxietyPsychiatric disorders | 0/26 | 2/26 | 0/25 | 0/26 |
| IrritabilityPsychiatric disorders | 0/26 | 2/26 | 0/25 | 0/26 |
| TachycardiaCardiac disorders | 1/26 | 2/26 | 1/25 | 0/26 |
| DyspepsiaGastrointestinal disorders | 0/26 | 0/26 | 1/25 | 0/26 |
| Age, Customized(Participants) | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo | Total |
|---|---|---|---|---|---|
| 6-12 Years | 16 | 16 | 16 | 16 | 64 |
| 13-17 Years | 10 | 10 | 9 | 10 | 39 |
| Sex: Female, Male(Participants) | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo | Total |
|---|---|---|---|---|---|
| Female | 13 | 10 | 9 | 9 | 41 |
| Male | 13 | 16 | 16 | 17 | 62 |
| Ethnicity (NIH/OMB)(Participants) | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 3 | 4 | 6 | 19 |
| Not Hispanic or Latino | 20 | 23 | 21 | 20 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 12 | 12 | 14 | 13 | 51 |
| White | 11 | 11 | 11 | 12 | 45 |
| More than one race | 3 | 2 | 0 | 1 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo | Total |
|---|---|---|---|---|---|
| United States | 26 | 26 | 25 | 26 | 103 |
| BMI Z-Score(Z-Score) | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 0.413 ± 0.8340 | 0.221 ± 1.0205 | 0.314 ± 1.1993 | 0.315 ± 0.9324 | 0.315 ± 0.9909 |
| BMI Percentile(Percentile) | 18.75 mg CTx-1301 (Dexmethylphenidate Tablet) | 25 mg CTx-1301 (Dexmethylphenidate Tablet) | 37.5 mg CTx-1301 (Dexmethylphenidate Tablet) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 62.84 ± 27.212 | 56.31 ± 31.410 | 62.40 ± 31.393 | 60.18 ± 29.309 | 60.41 ± 29.538 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Overall study data as required by FDAAA801 will be shared upon completion of the study.
Ran from Aug 2023 to primary completion in Feb 2024, 6 months.
Results were first posted in Jan 2026, 1 year 10 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 6 months is below that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CTX-1301
Attention Deficit Disorder with Hyperactivity →
Cingulate Therapeutics